Intercept Pharma (ICPT) Misses Q4 EPS by 11c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
What is Intercept Pharmaceuticals (ICPT) Value without NASH? RBC Capital Offers 3 Scenarios
February 24, 2021 6:47 AM ESTRBC Capital analyst Brian Abrahams reiterated a Sector Perform rating and $33.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after positing the question: What would Intercept be worth, without NASH? A string of recent events, both on the regulatory front and inside the company hint at the possibility that management may need... More
Intercept Pharma (ICPT) Announces Dagmar Rosa-Bjorkeson to Board
February 23, 2021 8:27 AM ESTIntercept Pharmaceuticals, Inc. (NASDAQ: ICPT) today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021.
Ms. Rosa-Bjorkeson has more than 25 years of global experience in the pharmaceutical industry, including executive leadership positions in corporate and product strategy, market development and operational execution. She is currently the Chief Operating Officer of Mesoblast Limited. Ms. Rosa-Bjorkeson has led... More
UPDATE: H.C. Wainwright Downgrades Intercept Pharmaceuticals (ICPT) to Sell
February 23, 2021 6:47 AM EST(Updated - February 23, 2021 7:01 AM EST)
H.C. Wainwright analyst Ed Arce downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Neutral to Sell, PT $25.00.
The analyst comments "In short, we no longer believe a viable regulatory path for OCA exists in... More
